

# Subba Digumarthy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11562517/publications.pdf>

Version: 2024-02-01

25  
papers

10,554  
citations

932766

10  
h-index

752256

20  
g-index

25  
all docs

25  
docs citations

25  
times ranked

13457  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. <i>Journal of Thoracic Oncology</i> , 2022, 17, 399-410.                             | 0.5 | 151       |
| 2  | Abstract 3580: Integrative genomics of checkpoint blockade response in advanced non-small cell lung cancer. <i>Cancer Research</i> , 2022, 82, 3580-3580.   | 0.4 | 0         |
| 3  | Phase I/II investigator-initiated study of olaparib and temozolomide in SCLC: Updated analysis and CNS outcomes.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8565-8565.  | 0.8 | 1         |
| 4  | Response to immune checkpoint inhibition as monotherapy or in combination with chemotherapy in metastatic ROS1-rearranged lung cancers.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9049-9049.                                   | 0.8 | 0         |
| 5  | Abstract LB197: An SU2C-Mark Foundation Lung collaborative update: integrative genomics identifies distinct transcriptional states associated with checkpoint blockade resistance. , 2021, , .  |     | 0         |
| 6  | Type I Collagenâ€‘targeted Positron Emission Tomography Imaging in Idiopathic Pulmonary Fibrosis: First-in-Human Studies. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 258-261.                     | 2.5 | 41        |
| 7  | Phase 2 study of tremelimumab plus durvalumab for previously-treated malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 8549-8549.  | 0.8 | 9         |
| 8  | Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score â‰¥90%.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9111-9111.   | 0.8 | 4         |
| 9  | Longitudinal analysis of plasma ALK mutations during treatment with next-generation ALK inhibitors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9068-9068.   | 0.8 | 0         |
| 10 | Efficacy of platinum-pemetrexed combination chemotherapy in ALK<i>+</i> non-small cell lung cancer refractory to second-generation ALK TKIs.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9067-9067.                              | 0.8 | 0         |
| 11 | Radiation dose reduction in chest dual-energy computed tomography: effect on image quality and diagnostic information. <i>Radiologia Brasileira</i> , 2018, 51, 377-384.  | 0.3 | 9         |
| 12 | Assessment of chest CT at CTDI<sub>vol</sub> less than 1â€‘mGy with iterative reconstruction techniques. <i>British Journal of Radiology</i> , 2017, 90, 20160625.  | 1.0 | 10        |
| 13 | Multifocal adenocarcinoma of the lung: Factors predictive for local therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20041-e20041.  | 0.8 | 1         |
| 14 | <i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Nonâ€‘Small Cell Lung Cancer: A Retrospective Analysis. <i>Clinical Cancer Research</i> , 2016, 22, 4585-4593. | 3.2 | 977       |
| 15 | Primary Paratracheal Leiomyoma: Increased Preoperative Diagnostic Specificity With Magnetic Resonance Imaging. <i>Annals of Thoracic Surgery</i> , 2016, 102, e151-e154.  | 0.7 | 2         |
| 16 | Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i>-Rearranged Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 1118-1133.   | 7.7 | 919       |
| 17 | Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rocicetinib. <i>JAMA Oncology</i> , 2016, 2, 541.  | 3.4 | 49        |
| 18 | Heterogeneity Underlies the Emergence of <i>EGFR</i> T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. <i>Cancer Discovery</i> , 2015, 5, 713-722.                          | 7.7 | 429       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Variation in mechanisms of acquired resistance (AR) among EGFR-mutant NSCLC patients with more than one post-resistant biopsy.. Journal of Clinical Oncology, 2014, 32, 8053-8053.         | 0.8  | 6         |
| 20 | Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. Oncologist, 2013, 18, 1214-1220.     | 1.9  | 119       |
| 21 | Potential Pitfall in the Assessment of Lung Cancer with FDG-PET/CT: Talc Pleurodesis Causes Intrathoracic Nodal FDG Avidity. Lung Cancer International, 2013, 2013, 1-6.                   | 1.2  | 6         |
| 22 | Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI).. Journal of Clinical Oncology, 2012, 30, 7524-7524. | 0.8  | 9         |
| 23 | Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors. Science Translational Medicine, 2011, 3, 75ra26.   | 5.8  | 2,938     |
| 24 | Detection of Mutations in EGFR in Circulating Lung-Cancer Cells. New England Journal of Medicine, 2008, 359, 366-377.  | 13.9 | 1,602     |
| 25 | Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature, 2007, 450, 1235-1239.   | 13.7 | 3,272     |